Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Practice
Open Access

How to use antihistamines

Derek K. Chu, Paul Oykhman and Gordon L. Sussman
CMAJ April 06, 2021 193 (14) E478-E479; DOI: https://doi.org/10.1503/cmaj.201959
Derek K. Chu
Division of Clinical Immunology and Allergy, Department of Medicine (Chu, Oykhman), and Department of Health Research Methods, Evidence & Impact (Chu), McMaster University and The Research Institute of St. Joe’s Hamilton, Ont.; Division of Clinical Immunology & Allergy (Sussman), Department of Medicine, University of Toronto, Toronto, Ont.
MD PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Oykhman
Division of Clinical Immunology and Allergy, Department of Medicine (Chu, Oykhman), and Department of Health Research Methods, Evidence & Impact (Chu), McMaster University and The Research Institute of St. Joe’s Hamilton, Ont.; Division of Clinical Immunology & Allergy (Sussman), Department of Medicine, University of Toronto, Toronto, Ont.
MD MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gordon L. Sussman
Division of Clinical Immunology and Allergy, Department of Medicine (Chu, Oykhman), and Department of Health Research Methods, Evidence & Impact (Chu), McMaster University and The Research Institute of St. Joe’s Hamilton, Ont.; Division of Clinical Immunology & Allergy (Sussman), Department of Medicine, University of Toronto, Toronto, Ont.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Antihistamines are among the most commonly and incorrectly used medicines worldwide

Antihistamine use is most strongly supported for treating allergic rhinoconjunctivitis (“hay fever”) and urticaria (hives).1–3 Avoid off-label usage for conditions where antihistamines have questionable utility, such as in managing asthma, eczema, cough or insomnia.

First-generation antihistamines are associated with substantial and sometimes fatal adverse effects

First-generation antihistamines (e.g., diphenhydramine [Benadryl], chlorpheniramine [Chlor-Tripolon], hydroxyzine [Atarax]) cause sedation, injury and impairment in sleep, and psychomotor and cognitive function, including impairing performance at school.1–3 Overdose can result in death from anticholinergic and anti-α-adrenergic effects, and QT prolongation (including torsades de pointes). First-generation antihistamines are on the Beers list of potentially inappropriate medications for older persons.3

Newer antihistamines are safer, as affordable and as efficacious as first-generation antihistamines

Compared with first-generation antihistamines, systematic reviews of randomized controlled trials have found newer antihistamines to be safer (e.g., 4% sedation v. 28%),2–4 longer lasting (12–24 h v. 4–6 h dosing) and faster acting (50 v. 80 min).1 The World Health Organization replaced chlorpheniramine with loratadine on its essential medicines list in 2013 for these reasons (see Table 1 and Appendix 1, available at www.cmaj.ca/lookup/doi/10.1503/cmaj.201959/tab-related-content for preferred antihistamines).3 Bilastine and fexofenadine are the least sedating options. However, no antihistamine should be consumed with alcohol.

View this table:
  • View inline
  • View popup
Table 1:

Summary of preferred antihistamines for allergy and urticaria

Antihistamines should not be used instead of epinephrine to treat anaphylaxis

Oral antihistamines can be used in addition to, but should not replace, epinephrine for the treatment of anaphylaxis.1,3 Intravenous diphenhydramine can cause vasodilation and sedation, which can worsen hypotension and confound assessment of patients with anaphylaxis.1,3

Most antihistamines are safe during pregnancy and breastfeeding

Systematic reviews of observational studies show no association with adverse fetal or maternal outcomes with antihistamine use during pregnancy or breastfeeding, and they are also safe for children.2,3,5 There is inadequate evidence regarding the newest antihistamines (rupatadine, bilastine) to support their use in pregnancy.

CMAJ invites submissions to “Five things to know about …” Submit manuscripts online at http://mc.manuscriptcentral.com/cmaj

Footnotes

  • Competing interests: Derek Chu is a CAAIF-CSACI-AllerGen Emerging Clinician-Scientist Research Fellow, supported by the Canadian Allergy, Asthma and Immunology Foundation, the Canadian Society of Allergy and Clinical Immunology and AllerGen NCE Inc. (the Allergy, Genes and Environment Network). Gordon Sussman reports grants and personal fees from Novartis, Aralez, CSL Behring, Sanofi, Pediapharm, GSK, Genentech, DBV technologies, Aimmune, AstraZeneca, Stallergenes, Merck, Pfizer, Dyax, Biocryst, Greencross, Kendrion, Shire, Leopharma, Regeneron and mdBriefCase and grants from Novartis, GSK, Genentech, DBV technologies, Aimmune, CSL Behring, AstraZeneca, Stallergenes, Merck, Pfizer, Dyax, Biocryst, Greencross, Kendrion, Leo Pharma, Regeneron, Sanofi, Blueprint, ALK, Amgen and Cliantha outside the submitted work. No other competing interests were declared.

  • This article has been peer reviewed.

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

References

  1. ↵
    1. Fein MN,
    2. Fischer DA,
    3. O’Keefe AW,
    4. et al
    . CSACI position statement: newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the firstline antihistamines for the treatment of allergic rhinitis and urticaria. Allergy Asthma Clin Immunol 2019;15:61.
    OpenUrl
  2. ↵
    1. Carson S,
    2. Lee N,
    3. Thakurta S
    . Drug class review: newer antihistamines: final report update 2. Portland (OR): Oregon Health & Science University; 2010.
  3. ↵
    1. Chahal H
    [for WHO Secretariat]. Section 3: Antiallergics and medicines used in anaphylaxis: histamine-1 receptor antagonists — a critical evaluation to update Section 3. Geneva: The World Health Organization; 2012.
  4. ↵
    1. Huang CZ,
    2. Jiang ZH,
    3. Wang J,
    4. et al
    . Antihistamine effects and safety of fexofenadine: a systematic review and meta-analysis of randomized controlled trials. BMC Pharmacol Toxicol 2019;20:72.
    OpenUrl
  5. ↵
    1. Gilboa SM,
    2. Ailes EC,
    3. Pai RP,
    4. et al
    . Antihistamines and birth defects: a systematic review of the literature. Expert Opin Drug Saf 2014;13:1667–98.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 193 (14)
CMAJ
Vol. 193, Issue 14
6 Apr 2021
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
How to use antihistamines
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
How to use antihistamines
Derek K. Chu, Paul Oykhman, Gordon L. Sussman
CMAJ Apr 2021, 193 (14) E478-E479; DOI: 10.1503/cmaj.201959

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
How to use antihistamines
Derek K. Chu, Paul Oykhman, Gordon L. Sussman
CMAJ Apr 2021, 193 (14) E478-E479; DOI: 10.1503/cmaj.201959
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Antihistamines are among the most commonly and incorrectly used medicines worldwide
    • First-generation antihistamines are associated with substantial and sometimes fatal adverse effects
    • Newer antihistamines are safer, as affordable and as efficacious as first-generation antihistamines
    • Antihistamines should not be used instead of epinephrine to treat anaphylaxis
    • Most antihistamines are safe during pregnancy and breastfeeding
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Utilisation appropriée des antihistaminiques
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • SARS-CoV-2 vaccination in pregnancy
  • Infantile perianal pyramidal protrusion
  • Topical nonsteroidal anti-inflammatory drugs
Show more Practice

Similar Articles

Collections

  • Article Types
    • Five Things to Know About
  • Topics
    • Allergy
    • Asthma
    • Drugs: adverse reactions
    • Family medicine, general practice, primary care
    • Immunology
    • Maternal-fetal medicine

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire